BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 3, 2003
View Archived Issues
Positive outcome for phase II study of Periostat as adjunctive treatment for rosacea
Read More
Preparations for Italian phase II Remune study
Read More
Antitumor effects described for FOLFOX4 + erlotinib in colorectal cancer
Read More
New therapies for fibromyalgia discussed at EULAR 2003
Read More
Requip OCR enters phase III testing
Read More
Approvable letter issued for Wellbutrin XL
Read More
Olux cleared for marketing in U.K.
Read More
FDA advisory committee issues positive decision on Photofrin PDT efficacy in Barrett's esophagus
Read More
MedImmune reviews pipeline progress
Read More
LAS-34475 reported safe and effective in the treatment of osteoarthritis
Read More
Antitumor effects described for homoharringtonine in acute and chronic leukemia
Read More
New inhibitors of ileal bile acid transport under study at Sankyo
Read More
Merck researchers identify alpha5-selective GABA-A receptor modulators for AD therapy
Read More
HER2 inhibitors prepared and tested by Takeda scientists
Read More
Novel series of p38 MAP kinase inhibitors in Ono pipeline
Read More
Morinaga Milk claims ACE-inhibitory tripeptide with in vivo antihypertensive activity
Read More
Novel potentiators of glucose transport designed by Ajinomoto researchers
Read More
Positive opinion for Onsenal in familial adenomatous polyposis in Europe
Read More
European CPMP recommends approval of Stalevo
Read More
Nycomed obtains license to commercialize MT-100 in Nordic countries
Read More
Multiple-dose phase I study of ETC-642 commences in stable atherosclerosis patients
Read More
Amgen exercises option to HuMax-IL-15
Read More
ABT-202, first compound to enter the clinic from NeuroSearch/Abbott collaboration
Read More
New phase I/II trial of Dacogen plus carboplatin for advanced solid tumors
Read More
Pivanex studied in combination with docetaxel for NSCLC
Read More
Indications for Forcaltonin expanded in Europe
Read More
Low-dose Prempro launched
Read More